Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q92771
UPID:
DDX12_HUMAN
Alternative names:
CHL1-related protein 2; DEAD/H box protein 12
Alternative UPACC:
Q92771
Background:
The Putative ATP-dependent RNA helicase DDX12, also known as CHL1-related protein 2 or DEAD/H box protein 12, plays a crucial role in cellular proliferation. Its primary function involves DNA helicase activity, which is likely essential for maintaining chromosome segregation, suggesting its pivotal role in cell division and genetic stability.
Therapeutic significance:
Understanding the role of Putative ATP-dependent RNA helicase DDX12 could open doors to potential therapeutic strategies. Its involvement in fundamental cellular processes highlights its potential as a target for interventions in diseases characterized by abnormal cell proliferation.